Basilea’s Toctino(R) Recommended For Approval In 15 Additional European Countries
Basilea Pharmaceutica Ltd. (SWISS: BSLN) announces that Toctino® (alitretinoin) was recommended for regulatory approval under the Repeat-use Procedure in 13 additional European Union (EU) Member States as well as in Norway and Iceland. Toctino® is a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids…
Also tagged Adults, Basilea, Bsln, Eczema, European Countries, Hand Eczema, Iceland, Member States, Norway, Oral Treatment, Regulatory Approval, Swiss, Topical Corticosteroids
